Precision Medicine - Biomarkers & Diagnostics

A funding opportunity to amplify medical and financial benefits of precision medicine

Acobiom’s diagnostics are part of a new generation of complex and high value-added molecular diagnostics. These blood-based diagnostic tests will improve the patient’s medical care in identifying those who are most likely to benefit from pre-determined treatments, while optimizing health care costs.

Blood‐based diagnostic tests dedicated to precision medicine

Acobiom is currently involved in the development of innovative Medical Diagnostics that can predict individual response of patients to pre-determined treatments. These blood-based diagnostic tests focused on Precision Medicine concern diseases with unmet medical needs.

Acobiom’s tests are non-invasive and can be performed from a simple blood sample (liquid biopsy). They are based on the measurement and the analysis (by proprietary algorithms) of a combination of several patented biological (molecular) markers. These Blood‐based Diagnostic Tests have been developing for routine uses on platforms already employed in central labs and clinical centers.

The benefits of Acobiom’s Diagnostics are helping choose the most adapted therapy for each patient, improve the patient’s quality of life during treatment, avoid phenomena of treatment resistance, reduce adverse effects and toxicities, avoide ineffective, uncomfortable and expensive treatments and, overall, improve the patient’s medical care.

A new generation of high added value molecular diagnostics

Whatever the therapeutic domain, several diagnostics capable to predict patient response to a treatment are already on the market. These predictive diagnostic tests are provided by companies as: Agendia, Genomic Health, Myriad Genetic, Qiagen, Roche, etc.
Acobiom’s predictive diagnostics are part of a new generation of complex and high added value molecular Diagnostics. Some of these diagnostics are commercial successes (see the graphs below): they showed impressive growing revenues as: Oncotype DX (Genomic Health) or AlloMap (CareDX).

Revenues oncotype


Acobiom, diagnostics to improve the medical care of patients suffering from cancers

Acobiom will commercialize its first predictive diagnostics in oncology. The company is thus positioned on the global market for company diagnostics (predictive diagnostics of response to a predetermined treatment) has been estimated at US$3.5 billion in 2016, and is likely to reach US$13.6 billion by 2025 (source: Transparency Market Research).

GemciTest® will be the first Acobiom’s predictive diagnostic. This testis focused on pancreatic cancer and its the commercialization is forecasted within the next coming months.

Moreover, the company will soon develop in-vitro diagnostics that will predict patient resistance to 1st line treatments in breast, lung and pancreatic cancers. Acobiom obtained a Bpifrance funding associated with this new R&D program called Oncosnipe.
The future diagnostics developed in this Oncosnipe project will grow the pipeline of diagnostics of the company and complete GemciTest in marketing and medical points of view.

Partners interested in the funding opportunity proposed by Acobiom can contact the company to obtain more information.